What is MapLight Therapeutics, Inc. 's net investment in lease?

MapLight Therapeutics, Inc. (MPLT) reported net investment in lease of $5.26M in Q1 2026.

MapLight Therapeutics, Inc. MPLT Net Investment in Lease

Net Investment in Lease at other companies

Neurocrine BiosciencesNBIX

——

Acadia PharmaceuticalsACAD

——

LBR

LB Pharmaceuticals Inc Common StockLBRX

——

MeiraGTx Holdings plcMGTX

——

Alto NeuroscienceANRO

——

Xenon PharmaceuticalsXENE

——

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B+100%

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's net investment in lease?: MapLight Therapeutics, Inc. (MPLT) reported net investment in lease of $5.26M in Q1 2026.